Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

(esmo), a leading global full-service systems integrator, developer, and supplier of innovative and advanced automation ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the most effective dose, above the 5% threshold deemed clinically ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective ...

New results from a pooled analysis of patients will be featured in a late-breaking presentation at the upcoming European ...

编者按： 2024年欧洲肿瘤内科学会亚洲年会（ESMO ASIA 2024）将于当地时间12月6日～8日在新加坡召开，将展示和讨论亚洲及全球肿瘤学领域的最新科学和临床研究，这些进展将进一步推动年末的学术交流热潮！近日ESMO ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...